The Leading Indicator

Executive Summary

Definium Therapeutics is a late-stage clinical biopharmaceutical company developing psychedelic- and empathogen-derived medicines for major depressive disorder (MDD), generalized anxiety disorder (GAD), and autism spectrum disorder (ASD), trading on Nasdaq under DFTX after rebranding from Mind Medicine (MindMed) in January 2026. Shares closed at $36.67 on June 22, 2026, up 49.80% on the day, after the company’s Phase 3 EMERGE trial of lead candidate DT120 in MDD met both its primary and key secondary endpoints, an 8.1-point placebo-adjusted reduction in MADRS at six weeks (13.3 points for DT120 against 5.2 for placebo) following a single 100-microgram dose, with benefit emerging within the first week and holding through twelve. The same day, the company also announced a $500 million public offering of common shares and pre-funded warrants, with underwriters holding a 30-day option for another $75 million, sending shares down roughly 5% after-hours even as the regular session closed at its best level in over two years. Market capitalization sits near $4.00 billion, against cash of approximately $373.4 million and total debt of $40.77 million; the company has guided to a cash runway into 2028 even before factoring in proceeds from the new offering. DT120 separately holds FDA Breakthrough Therapy Designation for GAD, where a Phase 3 program is underway, while the MDMA-derived DT402 remains in Phase 2a for ASD.

Homepage
Perplexity Finance Page
TradingView

Overview & Business Segments

Definium Therapeutics develops psychedelic-derived and empathogen-derived medicines for brain-health disorders, with its commercial case currently concentrated almost entirely on one molecule reaching two indications. The company traces its operating history to Mind Medicine (MindMed), with psychedelic-research activity dating to around 2019, and completed a formal rebrand to Definium Therapeutics, Inc. on January 9, 2026, with its US operating subsidiary renamed three days later. One market-data platform lists the underlying corporate entity’s founding year as 2010, predating the MindMed brand by roughly a decade, a discrepancy worth noting rather than resolving in either direction without checking the actual incorporation history. The company is incorporated in British Columbia, Canada, operates through Delaware-incorporated US subsidiaries, and is reported as headquartered in New York, though a precise street address was not located in sources reviewed.

• Full name and history: Definium Therapeutics Inc., formerly Mind Medicine (MindMed) Inc.; rebrand effective January 9, 2026 (corporate) and January 12, 2026 (US subsidiary, now Definium Therapeutics US, Inc.).
• Founders: one market-data source names Stephen L. Hurst, Scott M. Freeman, and a third individual whose name was truncated in the source (“Leona…”) as company founders; this should be confirmed against the company’s own filings before being treated as a complete list.
• Stated mission: to “forge a new era of psychiatry” by applying clinical rigor to psychedelic compounds in pursuit of scalable, accessible treatment.
• Lead pipeline asset: DT120, an orally disintegrating tablet formulation of lysergide D-tartrate (LSD-derived), targeting GAD and MDD. The EMERGE trial (MDD) read out positively in June 2026; a second Phase 3 MDD trial, internally referred to as Ascend, dosed its first patient May 12, 2026; the GAD Phase 3 program is separately underway, though no specific trial name for it was confirmed in sources reviewed.
• Second pipeline asset: DT402, the R-enantiomer of MDMA, in Phase 2a for ASD.
• Wholly owned subsidiary: HealthMode, Inc., a digital-biomarker and measurement-technology business acquired during the company’s MindMed era, now integrated into the platform’s clinical measurement tools.

Leadership & Governance

Robert Barrow is CEO of Definium Therapeutics, confirmed across multiple sources including direct quotation in Reuters coverage of the company’s regulatory strategy. Beyond the CEO, individual executive and board detail remains thin in sources reviewed; ownership data, however, is now available and tells its own story. Free float stands at approximately 104.84 million shares, 96.12% of the roughly 109.07 million shares outstanding, with only 4.23 million shares (3.88%) closely held. That is a meaningfully more dispersed ownership structure than is typical for a company this age, with no obvious founder or insider control block of the kind that would concentrate governance risk the way it does at some peer biotechs.

• CEO: Robert Barrow, confirmed via company statements and direct press quotation.
• Founders named in one source: Stephen L. Hurst, Scott M. Freeman, and a third name truncated in that source; unconfirmed against primary filings.
• No CFO, CMO, or board members are named in any source reviewed; consult the company’s most recent proxy statement or 10-K/10-Q directly for current detail.
• Ownership: 96.12% free float, 3.88% closely held, out of roughly 109.07 million total shares outstanding; no dual-class structure or supermajority control block identified in sources reviewed.
• A June 11, 2026 shareholder meeting approved director elections, an auditor appointment, and an equity plan amendment, the only concrete governance event confirmed in the available record beyond the rebrand itself.

Market Position & Competitors

Definium sits at the intersection of psychedelic medicine and mainstream psychiatric pharmacotherapy, and its positive Phase 3 MDD result puts it ahead of most psychedelic-sector peers still running Phase 2 programs. Needham analyst Ami Fadia called the EMERGE result “unprecedented in the depression space,” noting the week-six effect size exceeded what Johnson & Johnson’s Spravato and Compass Pathways’ COMP360 achieved at week four, a direct, sourced efficacy comparison rather than a general claim of leadership.

• Compass Pathways (CMPS): psilocybin-based therapy in Phase 3 for treatment-resistant depression; the closest regulatory and payer precedent-setter in the sector, and one of three companies granted expedited FDA review in April 2026.
• Atai Life Sciences / AtaiBeckley (ATAI): multi-asset psychedelic and neuromodulation platform; recent coverage refers to the company as “AtaiBeckley,” suggesting a possible merger or rebrand with Beckley Psytech that should be verified before being treated as settled. Its CEO, Srinivas Rao, is developing BPL-003, an intranasal 5-MeO-DMT formulation for treatment-resistant depression.
• GH Research (GHRS): 5-MeO-DMT-based treatment for treatment-resistant depression and related indications.
• Cybin Inc. (CYBN): deuterated psychedelic derivatives aimed at improved pharmacokinetics for depression and anxiety.
• Non-psychedelic MDD comparables: Johnson & Johnson’s Spravato (esketamine), Axsome Therapeutics’ Auvelity, and Sage Therapeutics’ Zurzuvae, the conventional-pharmacology benchmarks DT120’s efficacy is now being measured against directly in sell-side notes.
• As a pre-revenue clinical company, conventional market-share metrics do not yet apply; Definium’s edge currently rests on clinical stage, Breakthrough Therapy Designation, and a head-to-head efficacy comparison sell-side analysts are already making in its favor.

Financials & Capital Structure

Definium’s spending stepped up sharply alongside its move into late-stage trials, and the company remains entirely pre-revenue, with analyst revenue models showing the first nonzero figures only from 2027 onward. The same day as its strongest clinical readout in years, the company also announced its largest near-term dilution event, worth holding in view at the same time as the clinical result rather than as a separate story.

• Accumulated deficit: approximately $582.7 million as of December 31, 2025.
• Q1 2026 results: revenue of $0; net loss of $77.1 million; EPS of −$0.71, missing consensus of −$0.49 and following a recent pattern of missed quarterly estimates.
• Q1 2026 R&D spend: $41.5 million, up from $23.4 million in Q1 2025; G&A spend $17.7 million, up from $8.8 million.
• Balance sheet, most recent snapshot: cash and equivalents of approximately $373.4 million, total debt of $40.77 million, enterprise value of approximately $3.67 billion against a market cap near $4.00 billion.
• Company guidance points to a cash runway into 2028, a figure stated before accounting for the newly announced offering.
• Newly announced financing: a $500 million underwritten public offering of common shares and pre-funded warrants, with a 30-day underwriter option for an additional $75 million, announced the same day as the EMERGE readout; proceeds are earmarked for R&D, potential DT120 commercialization, and general corporate purposes.
• Sell-side revenue estimates show $0 through 2026, then $29.6 million (2027), $203.3 million (2028), and $505.6 million (2029); EPS estimates over the same span move from roughly −$2.28 (2026) to −$1.67 (2027) to −$0.85 (2028) to a projected +$0.89 (2029), implying analyst models assume DT120 reaches commercial profitability within that window.

Public Market Information & Valuation

DFTX trades on Nasdaq under a listing history that predates the 2026 rebrand, carried over from the prior MindMed (MNMD) ticker; one data platform still lists the company’s website as the legacy mindmed.co domain rather than the current definiumtx.com, worth noting as a minor but real inconsistency in how cleanly the rebrand has propagated across data vendors.

• Ticker and exchange: DFTX, Nasdaq Stock Market; ISIN/CUSIP not confirmed in sources reviewed.
• Price and move: closed at $36.67 on June 22, 2026, up 49.80% on the day, the stock’s best single-day performance in over two years.
• Market capitalization: approximately $4.00 billion at that close.
• Analyst price targets, pre- and post-readout: the prior consensus 12-month target stood at $38.00 as of early May 2026; following the readout, Canaccord Genuity raised its target to $60 (from $38, Buy), RBC Capital Markets to $57 (from $36, Outperform), while Jefferies held a $35 target (Buy) but said the stock could still rise another 50–100%. The broader current consensus across 15 analysts sits at an average of $49.40 (range $25.00 to $70.00).
• Analyst rating distribution: 15 Strong Buy, 1 Buy, 0 Hold, 0 Sell, 0 Strong Sell across 16 analysts in the trailing three months, an unusually one-sided consensus with no bearish counterweight currently represented.
• Other coverage: Outperform ratings maintained by Leerink Partners and Oppenheimer, Overweight maintained by Piper Sandler; Needham and Stifel both issued strongly positive commentary on the EMERGE data without confirmed specific price-target changes in sources reviewed.
• 1-year performance: reported between roughly 169% and 174% year-to-date depending on source and date measured, with repeated appearances on top-gainer, unusual-volume, and 52-week-high screens.

Strategic, Regulatory & Risk Factors

Definium’s core strategic asset, positive Phase 3 data paired with Breakthrough Therapy Designation, is also the source of its core scrutiny, and it now sits inside a genuinely shifting regulatory environment rather than a static one. In April 2026, President Trump signed an executive order directing the FDA and DEA to improve coordination on psychedelic drug development, including a provision allowing DEA scheduling work to begin once late-stage data exists rather than waiting for full FDA approval. Barrow himself was quoted welcoming that specific provision as a potential efficiency gain. The same month, the FDA granted expedited review to three other psychedelic developers, Compass Pathways, Usona Institute, and Transcend Therapeutics, a sign of genuine regulatory momentum rather than a one-off favor to a single company.

• Regulatory pathway: Breakthrough Therapy Designation applies specifically to DT120 in GAD; the MDD readout that moved the stock came from the separate EMERGE trial, and the two indications should not be conflated when assessing regulatory timeline.
• Regulatory tailwind: the April 2026 executive order’s DEA-scheduling provision and improved FDA-DEA coordination were cited by Definium’s own CEO as a potential source of efficiency gains specific to this company’s timeline.
• Litigation and enforcement: no lawsuits, antitrust actions, or government enforcement proceedings specific to Definium were found in sources reviewed; absence of evidence in the sources available is not proof of absence.
• Sector-wide reimbursement risk: even sector investors interviewed alongside the executive order coverage noted that faster FDA review does not resolve insurance-reimbursement uncertainty, an unanswered question for psychedelic-derived medicines generally.
• Dilution risk, now realized rather than hypothetical: the $500 million-plus offering announced alongside the readout is the concrete expression of the financing risk this entry has flagged throughout; retail sentiment trackers showed explicit investor concern about the resulting dilution within hours of the announcement.
• Concentration and consensus risk: the pipeline depends heavily on one lead asset across two indications, and the current 15-Strong-Buy, zero-Sell analyst consensus leaves no visible bearish counterweight, a one-sidedness that is itself worth treating as a risk factor rather than as confirmation.

Price Charts

TradingView

---

Sources

[1] Mind Medicine (MindMed) Inc. Stock Price — Perplexity — https://www.perplexity.ai/finance/MNMD/earnings [2] Pharmaceuticals: Major — Industry Performance, USA — TradingView — https://www.tradingview.com/markets/stocks-usa/sectorandindustry-industry/pharmaceuticals-major/ [3] Definium Therapeutics (DFTX) Sees Significant Surge in Stock Price — GuruFocus — https://www.gurufocus.com/news/8925486/definium-therapeutics-dftx-sees-significant-surge-in-stock-price [4] Why is Definium Therapeutics stock soaring nearly 40% today? — Investing.com — https://www.investing.com/news/stock-market-news/why-is-definium-therapeutics-stock-soaring-nearly-40-today-93CH-4752436 [5] Why Definium Therapeutics (DFTX) Stock Is Up 52% Today — CoinCentral — https://coincentral.com/why-definium-therapeutics-dftx-stock-is-up-52-today/ [6] This Biotech’s LSD-Based Drug Just Treated Depression. Now The Stock Is Sky-High. — Investor’s Business Daily — https://www.investors.com/news/technology/definium-therapeutics-stock-lsd-depression-treatment/ [7] Definium Therapeutics, Inc. — Overview — Twelve Data — https://twelvedata.com/markets/612062/stock/fsx/mmq0 [8] Definium Therapeutics (DFTX) 10-K Form and Latest SEC Filings 2026 — MarketBeat — https://www.marketbeat.com/stocks/NASDAQ/DFTX/sec-filings/ [9] Description of the Business — SEC EDGAR — https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/R10.htm [10] Definium Therapeutics (Nasdaq: DFTX) — Stock Analysis — Simply Wall St — https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dftx/definium-therapeutics [11] Definium’s depression pill posts Phase 3 win, with 8.1-point gap — StockTitan — https://www.stocktitan.net/news/DFTX/definium-therapeutics-announces-positive-topline-results-from-phase-h1acvvzulhi4.html [12] Definium Therapeutics (DFTX) Stock Price, Quote, News — Benzinga — https://www.benzinga.com/quote/DFTX [13] DFTX Insider Activity — Nasdaq — https://www.nasdaq.com/market-activity/stocks/dftx/insider-activity [14] Definium Therapeutics Inc. (DFTX) — Insider Trading — SEC Form 4 — https://www.secform4.com/insider-trading/1813814.htm [15] Definium Therapeutics – DFTX – Stock Price & News — The Motley Fool — https://www.fool.com/quote/nasdaq/dftx/ [16] DFTX Stock Price Quote & News — Robinhood — https://robinhood.com/us/en/stocks/DFTX/

. . .

[1] Mind Medicine (MindMed) Inc. Stock Price — Perplexity — https://www.perplexity.ai/finance/MNMD/earnings
[2] Pharmaceuticals: Major — Industry Performance, USA — TradingView — https://www.tradingview.com/markets/stocks-usa/sectorandindustry-industry/pharmaceuticals-major/
[3] Definium Therapeutics, Inc. — Overview — Twelve Data — https://twelvedata.com/markets/612062/stock/fsx/mmq0
[4] Description of the Business — SEC EDGAR — https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/R10.htm
[5] Definium Therapeutics (Nasdaq: DFTX) — Stock Analysis — Simply Wall St — https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dftx/definium-therapeutics
[6] DFTX Insider Activity — Nasdaq — https://www.nasdaq.com/market-activity/stocks/dftx/insider-activity
[7] Definium Therapeutics Inc. (DFTX) — Insider Trading — SEC Form 4 — https://www.secform4.com/insider-trading/1813814.htm
[8] Definium Therapeutics — DFTX — Stock Price & News — The Motley Fool — https://www.fool.com/quote/nasdaq/dftx/
[9] DFTX Stock Price Quote & News — Robinhood — https://robinhood.com/us/en/stocks/DFTX/
[10] DFTX Stock Clocks Best Day In Over Two Years On ‘Best-Case’ Clinical Results For Oral Lysergide In Depression — TradingView News (Stocktwits) — https://www.tradingview.com/symbols/NASDAQ-DFTX/
[11] Under the Radar: Definium Shares Propelled by Strong Psychedelic Results — WSJ — via TradingView News
[12] Definium’s LSD-based depression pill delivers strong late-stage results, shares surge — Reuters — via TradingView News
[13] Trump’s psychedelic drug order boosts investor interest with promise of faster reviews — Reuters — via TradingView News
[14] Definium Therapeutics Inc reports results for the quarter ended March 31 — Earnings Summary — Refinitiv — via TradingView News
[15] Definium Therapeutics, Inc. — Perplexity Finance (Overview, Financials, Forecasts) — https://www.perplexity.ai/finance/DFTX